Aktis Oncology, Inc. (AKTS) vs LB Pharmaceuticals Inc (LBRX)
Aktis Oncology, Inc. and LB Pharmaceuticals Inc are both Biotechnology companies. LB Pharmaceuticals Inc is the larger, with a market value of $1.2B against $1.1B — 1.1× the size. LB Pharmaceuticals Inc has the higher net margin (0.00% vs −782.0%) and the lower return on invested capital (−1,304.8% vs 0.00%). Across the 12 metrics below, Aktis Oncology, Inc. leads on 6 and LB Pharmaceuticals Inc on 6.
Valuation
Profitability
| Metric | AKTS | LBRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | — | 65.16% |
| Operating margin | (939.13%) | 0.00% | 0.00% |
| Net margin | (781.95%) | 0.00% | 0.00% |
| Free cash flow margin | (1,442.91%) | 0.00% | 0.00% |
| Return on equity | (34.45%) | (72.07%) | (57.72%) |
| Return on assets | (27.09%) | (47.38%) | (49.22%) |
| Return on invested capital | 0.00% | (1,304.79%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack